Curated · Healthcare

Biotech

By InspectStocksPublished Oct 14, 202619 companies0 followers

Drug developers with approved medicines, built mainly on biologic and genetic science.

Grouped with the help of an AI model and reviewed by our editors. The line under each company says why it is here.

Download image

Cards Tiers

Share prices are the Nov 11, 2026 close, from the IEX exchange feed.

Grade mix

A 8B 4C 5D 1F 1

Revenue growing

18 of 19

Free cash flow growing

13 of 18

Median price move, 1 year

+29.0%

Sort by

VRTXVERTEX PHARMACEUTICALS INC / MA
BiotechnologyMarket cap $138.7BP/E 35.22
$547.02+26.0%1Y
Since added +12.7%
B+
Growth & cash
Growing strongly
Business trend
Steady
Business quality
Strong
Getting better
Improving
Revenue
$13B+10.5%
Profit
$4B+8.2%
Free cash flow
$3.2B-4.0%
Discuss
Why it is here: Develops and sells cystic fibrosis and other medicines
REGNREGENERON PHARMACEUTICALS, INC.
BiotechnologyMarket cap $101.3BP/E 21.18
$959.45+41.5%1Y
Since added +27.4%
C+
Growth & cash
Growing
Business trend
Accelerating
Business quality
Strong
Getting better
Improving
Revenue
$16.9B+18.6%
Profit
$4.8B+5.2%
Free cash flow
$3.8B-9.4%
Discuss
Why it is here: Develops and sells antibody therapies for eye, allergy and cancer conditions
GILDGILEAD SCIENCES, INC.
Drug manufacturers generalMarket cap $210.5BNo P/E (operating loss)
$169.73+40.9%1Y
Since added +14.8%
A
Growth & cash
Growing strongly
Business trend
Steady
Business quality
Mixed
Getting better
Improving
Revenue
$31B+6.5%
Profit
-$3.9B-147.6%
Free cash flow
$13.8B+50.4%
Discuss
Why it is here: Sells medicines for HIV, liver disease and cancer
ALNYALNYLAM PHARMACEUTICALS, INC.
BiotechnologyMarket cap $21.4BP/E 68.58
$159.80-64.7%1Y
Since added -28.6%
B+
Growth & cash
Growing strongly
Business trend
Slowing
Business quality
Strong
Getting better
Improving
Revenue
$3.7B+65.2%
Profit
$2.6B+2,136.9%
Free cash flow
$465.4M+1,192.7%
Discuss
Why it is here: Develops and sells RNAi therapeutics
BIIBBIOGEN INC.
Drug manufacturers generalMarket cap $37.5BP/E 109.22
$253.39+56.9%1Y
Since added +10.7%
A
Growth & cash
Growing strongly
Business trend
Steady
Business quality
Solid
Getting better
Mixed
Revenue
$10.3B+2.3%
Profit
$347.5M-78.4%
Free cash flow
$2.1B-10.1%
Discuss
Why it is here: Develops and sells therapies for neurological diseases
INSMINSMED INC
BiotechnologyMarket cap $26.5BNo P/E (operating loss)
$120.64-37.9%1Y
Since added +24.7%
C-
Growth & cash
Growing
Business trend
Steady
Business quality
Weak
Getting better
Mixed
Revenue
$1.5B+240.0%
Profit
-$605.6M+48.8%
Free cash flow
-$627.6M+30.7%
Discuss
Why it is here: Develops and sells therapies for rare lung diseases
UTHRUnited Therapeutics Corporation
Drug manufacturers specialty and genericMarket cap $25.4BP/E 22.48
$595.58+29.0%1Y
Since added +9.6%
C+
Growth & cash
Growing strongly
Business trend
Slowing
Business quality
Strong
Getting better
Improving strongly
Revenue
$3.2B+1.9%
Profit
$1.2B-3.2%
Free cash flow
$867.2M-22.7%
Discuss
Why it is here: Sells therapies for pulmonary arterial hypertension
NBIXNEUROCRINE BIOSCIENCES, INC.
Drug manufacturers specialty and genericMarket cap $17.6BP/E 25.87
$174.35+18.7%1Y
Since added +29.0%
A+
Growth & cash
Growing strongly
Business trend
Accelerating
Business quality
Strong
Getting better
Improving
Revenue
$3.7B+38.0%
Profit
$702.5M+64.1%
Free cash flow
$1B+75.3%
Discuss
Why it is here: Develops and sells therapies for neurological and endocrine disorders
MRNAModerna, Inc.
BiotechnologyMarket cap $100.6BNo P/E (operating loss)
$248.70+831.1%1Y
Since added +15.0%
C-
Growth & cash
Growing
Business trend
Accelerating
Business quality
Weak
Getting better
Deteriorating
Revenue
$2.5B+13.1%
Profit
-$2.8B+10.5%
Free cash flow
-$2B+25.7%
Discuss
Why it is here: Develops mRNA vaccines and therapies
BMRNBioMarin Pharmaceutical Inc
BiotechnologyMarket cap $11.3BNo P/E
$58.32+5.4%1Y
Since added +7.3%
B
Growth & cash
Growing strongly
Business trend
Steady
Business quality
Mixed
Getting better
Improving
Revenue
$3.7B+18.1%
Profit
-$19.1M-103.7%
Free cash flow
$557.9M-33.0%
Discuss
Why it is here: Develops and sells therapies for rare genetic diseases
INCYINCYTE CORPORATION
BiotechnologyMarket cap $24.9BP/E 65.01
$122.23+12.9%1Y
Since added +12.6%
C
Earnings & book value
Growing
Business quality
Mixed
Getting better
Improving strongly
Revenue
$6B+24.9%
Profit
$403.4M-66.1%
Free cash flow
$892.1MNo comparable year
Discuss
Why it is here: Develops and sells oncology and inflammation therapies
EXELEXELIXIS, INC.
BiotechnologyMarket cap $17.3BP/E 21.17
$70.71+62.2%1Y
Since added +18.8%
A+
Growth & cash
Growing strongly
Business trend
Steady
Business quality
Strong
Getting better
Improving
Revenue
$2.5B+9.1%
Profit
$885.1M+30.6%
Free cash flow
$1.2B+48.9%
Discuss
Why it is here: Develops and sells cancer therapies
BNTXBioNTech SE
BiotechnologyMarket cap $22BNo P/E (operating loss)
$87.64-21.5%1Y
Since added -1.5%
F
Growth & cash
Mixed
Business trend
Contracting
Business quality
Mixed
Getting better
Improving
Revenue
$2.7B-23.2%
Profit
-$1.6B-157.7%
Free cash flow
$314M+456.5%
Discuss
Why it is here: Develops mRNA vaccines and cancer therapies
JAZZJazz Pharmaceuticals plc
BiotechnologyMarket cap $15.9BP/E 80.84
$248.18+81.5%1Y
Since added +18.0%
A
Growth & cash
Growing strongly
Business trend
Steady
Business quality
Mixed
Getting better
Improving
Revenue
$4.7B+13.5%
Profit
$206M+155.9%
Free cash flow
$1.6B+21.3%
Discuss
Why it is here: Develops and sells neuroscience and oncology therapies
HALOHALOZYME THERAPEUTICS, INC.
BiotechnologyMarket cap $11.6BP/E 25.36
$101.69+44.0%1Y
Since added -7.2%
A+
Growth & cash
Growing strongly
Business trend
Steady
Business quality
Strong
Getting better
Improving
Revenue
$1.8B+45.0%
Profit
$485.4M-18.5%
Free cash flow
$885.9M+47.1%
Discuss
Why it is here: Licenses drug delivery technology and sells enzyme-based therapies
ASNDAscendis Pharma A/S
BiotechnologyMarket cap $16.1BNo P/E (operating loss)
$259.10+30.1%1Y
Since added +16.0%
D
Earnings & book value
Mixed
Business quality
Mixed
Getting better
Improving
Revenue
$1.2B+113.4%
Profit
-$254.8M+39.7%
Free cash flow
-$293.2M+54.2%
Discuss
Why it is here: Develops and sells endocrinology rare disease therapies
BBIOBridgeBio Pharma, Inc.
BiotechnologyMarket cap $15.5BNo P/E (operating loss)
$79.53+20.1%1Y
Since added +25.6%
B
Growth & cash
Growing strongly
Business trend
Steady
Business quality
Mixed
Getting better
Deteriorating
Revenue
$945.5M+167.3%
Profit
-$573.8M+28.6%
Free cash flow
-$369.8M+36.9%
Discuss
Why it is here: Develops therapies for genetic diseases
CORTCORCEPT THERAPEUTICS INC
BiotechnologyMarket cap $8.2BP/E 58.68
$74.52-4.9%1Y
Since added -36.7%
A+
Growth & cash
Growing strongly
Business trend
Accelerating
Business quality
Strong
Getting better
Mixed
Revenue
$963.6M+30.0%
Profit
$162.3M+52.9%
Free cash flow
$194.6M+19.2%
Discuss
Why it is here: Develops and sells cortisol-modulating therapies
KRYSKrystal Biotech, Inc.
BiotechnologyMarket cap $9.2BP/E 41.90
$308.82+52.1%1Y
Since added -3.9%
A+
Growth & cash
Growing strongly
Business trend
Steady
Business quality
Strong
Getting better
Improving
Revenue
$470M+26.0%
Profit
$225.2M+13.2%
Free cash flow
$310.1M+87.3%
Discuss
Why it is here: Develops and sells topical gene therapies for rare diseases

Green and red compare each figure with the same window a year earlier. Grades and checks are the company page's own; nothing here is a recommendation.

DiscussionNo comments yet

Be civil and stick to the companies. Comments are opinions, not advice.

Lists are their owners' own, and notes and comments are opinions. Grades describe businesses from their filings; nothing here is a recommendation to buy or sell.